Thomas Berg, Prof.Dr. Study Chair Leipzig Peter R. Galle, Prof.Dr. Study Chair Mainz Wolf P. Hofmann, Prof.Dr. Study Chair Berlin Achim Kautz Study Chair Köln Philippe Pereira, Prof.Dr. Study Chair Heilbronn Karin Potthoff, Dr. Study Chair Freiburg im Breisgau Jan Schröder, PD Dr. Study Chair Mülheim an der Ruhr Robert Thimme, Prof.Dr. Study Chair Freiburg im Breisgau
1. Course of treatment (treatment reality). (Time Frame - 3 years per patient.): Documentation of anamnestic data and therapy sequences.
Secondary outcome:
1. Best Response. (Time Frame - 3 years per patient.): Documentation of response rates per line of treatment.
2. Progression-free survival. (Time Frame - 3 years per patient.): Documentation of progression-free survival per line of treatment.
3. Overall survival. (Time Frame - 3 years per patient.): Documentation of overall survival per line of treatment.
4. Health-related quality of life (Patient-reported outcome, PRO). (Time Frame - 3 years per patient.): EORTC QLQ-C30 core questionnaire [European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire; Scale 0-100; a high scale score represents a higher response level: (a) global health status: a high score represents high quality of life, (b) functional scales: a high score represents high/healthy level of functioning, (c) symptom scales/items: a high score represents high level of symptomatology or problems]
5. Carcinoma Health-related quality of life (Patient-reported outcome, PRO). (Time Frame - 3 years per patient.): EORTC QLQ-HCC18, the hepatocellular carcinoma specific module / EORTC QLQ-BIL21, the cholangiocarcinoma specific module [European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire; Scale 0-100; a high score for scales and single items represents a high level of symptomatology or problems].
